Literature DB >> 16000844

Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis.

Nobuyuki Ohike1, Toshio Morohoshi.   

Abstract

The prognostic significance of several pathological factors (tumor size, mitotic index, Ki-67 labeling index, and vascular invasion) and expression of exocrine markers (CA19-9, CEA, AFP, and trypsin) in pancreatic endocrine tumors was studied. A total of 20 specimens of metastasizing (n = 10) and non-metastasizing (n = 10) tumors were subjected to histological and immunohistochemical examination. The metastasizing tumors showed significantly larger size, higher Ki-67 labeling index, increased number of mitotic cells, and more frequent vascular invasion in comparison with the non-metastasizing tumors. It was difficult to determine the effect of individual factors on clinical outcome because of slow disease progression in almost all cases. Numerous mitotic cells and widespread necrosis, however, were thought to indicate a poor prognosis, and tumors with these characteristics were regarded as high-grade malignant endocrine carcinomas. In one case, one-third of the tumor tissue comprised trypsin-positive cells, the outcome was comparatively poor, and the behavior of the tumor resembled that of mixed acinar-endocrine carcinoma. A simple multifactorial approach may be effective for the identification of tumors at increased risk of metastasis, but it remains difficult to determine clinical prognosis. It is essential to at least distinguish high-grade endocrine carcinomas from the more common endocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000844     DOI: 10.1385/ep:16:1:033

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  19 in total

Review 1.  Mixed exocrine-endocrine tumors of the pancreas.

Authors:  G Klöppel
Journal:  Semin Diagn Pathol       Date:  2000-05       Impact factor: 3.464

2.  Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation.

Authors:  N Ohike; T Morohoshi
Journal:  Pathol Int       Date:  2001-10       Impact factor: 2.534

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors.

Authors:  A Gentil Perret; J F Mosnier; J P Buono; P Berthelot; J Chipponi; J G Balique; J Cuilleret; P Dechelotte; S Boucheron
Journal:  Am J Clin Pathol       Date:  1998-03       Impact factor: 2.493

5.  Mixed acinar-endocrine carcinomas of the pancreas.

Authors:  D S Klimstra; J Rosai; C S Heffess
Journal:  Am J Surg Pathol       Date:  1994-08       Impact factor: 6.394

6.  Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma, and solid cystic (papillary-cystic) tumor.

Authors:  T Morohoshi; M Kanda; A Horie; A Chott; T Dreyer; G Klöppel; P U Heitz
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

7.  Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas.

Authors:  G Pelosi; G Zamboni; C Doglioni; S Rodella; E Bresaola; C Iacono; G Serio; A Iannucci; A Scarpa
Journal:  Am J Surg Pathol       Date:  1992-12       Impact factor: 6.394

8.  Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations.

Authors:  S K Libutti; P L Choyke; D L Bartlett; H Vargas; M Walther; I Lubensky; G Glenn; W M Linehan; H R Alexander
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

9.  Proliferative Activity in Pancreatic Endocrine Tumors: Association with Function, Metastases, and Survival.

Authors:  Martha R. Clarke; Evan E. Baker; Robert J. Weyant; Lisa Hill; Sally E. Carty
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

10.  Insulinoma. An immunocytochemical and morphologic analysis of 95 cases.

Authors:  T H Liu; H C Tseng; Y Zhu; S X Zhong; J Chen; Q C Cui
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

View more
  5 in total

1.  Mixed acinar-endocrine carcinoma of the pancreas with intraductal growth into the main pancreatic duct: Report of a case.

Authors:  Shinjiro Kobayashi; Takeshi Asakura; Nobuyuki Ohike; Takeharu Enomoto; Joe Sakurai; Satoshi Koizumi; Taiji Watanabe; Hiroshi Nakano; Takehito Otsubo
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

2.  Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.

Authors:  David A Kleiman; Toni Beninato; Samuel Sultan; Michael J P Crowley; Brendan Finnerty; Ritu Kumar; Nicole C Panarelli; Yi-Fang Liu; Michael D Lieberman; Marco Seandel; Todd Evans; Olivier Elemento; Rasa Zarnegar; Thomas J Fahey
Journal:  Ann Surg Oncol       Date:  2014-05-23       Impact factor: 5.344

Review 3.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

4.  Acinar cell carcinoma of the pancreas: clinical and cytomorphologic characteristics.

Authors:  Adam D Toll; Ralph H Hruban; Syed Z Ali
Journal:  Korean J Pathol       Date:  2013-04-24

5.  Endocrine tumors of the gastrointestinal tract and pancreas: grading, tumor size and proliferation index do not predict malignant behavior.

Authors:  Borislav A Alexiev; Cinthia B Drachenberg; John C Papadimitriou
Journal:  Diagn Pathol       Date:  2007-08-08       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.